Similarities and Differences between Olaparib (Olaparib, Lipdro) and Niraparib

Olaparib (Olaparib, Lipadro) and niraparib, as two PARP inhibitors, are widely used in tumor treatment, especially the treatment of ovarian cancer. Both olaparib and niraparib are PARP (polymerase-associated adenosine diphosphate ribose polymerase) inhibitors. They affect the DNA repair ability of tumor cells by inhibiting the activity of PARP enzyme, thereby inducing tumor cell death. Both are mainly used to treat malignant tumors such as ovarian cancer. Lynparib's indications include ovarian cancer, breast cancer, etc., while niraparib is mainly used for maintenance treatment of platinum-sensitive relapsed ovarian cancer. Both have shown significant efficacy in specific patient populations, particularly those with BRCA gene mutations or platinum sensitivity.

The half-life of niraparib is as long as36 hours, so it only needs to be taken orally once a day, making the medication more convenient and patient compliance is relatively high. Olaparib has a relatively short half-life and is usually taken by mouth twice daily.

Niraparib is less affected by food and drugs because it is metabolized and absorbed by carboxylesterase, unlike many drugs that are metabolized by CYP3Aenzyme, which makes taking niraparib more convenient. Olaparib may interact with other medications, requiring additional medication precautions.

Olaparib has a relatively wider range of indications, including ovarian cancer, breast cancer and other malignant tumors. It is also a first-line treatment drug for breast cancer and a first-line maintenance treatment drug for ovarian cancer recommended by NCCN clinical guidelines. Niraparib is the world's first PARP inhibitor approved for the maintenance treatment of all patients with platinum-sensitive recurrent ovarian cancer, regardless of BRCA mutation.

Both drugs may cause some adverse reactions, such as anemia, nausea, etc., but the specific manifestations and severity may vary depending on individual differences.